Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Exelixis Inc (EXEL)
Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,472,928
  • Shares Outstanding, K 325,600
  • Annual Sales, $ 1,611 M
  • Annual Income, $ 182,280 K
  • 60-Month Beta 0.68
  • Price/Sales 3.84
  • Price/Cash Flow 30.21
  • Price/Book 2.41
Trade EXEL with:

Options Overview Details

View History
  • Implied Volatility 30.50% ( -8.23%)
  • Historical Volatility 22.26%
  • IV Percentile 14%
  • IV Rank 26.05%
  • IV High 59.42% on 07/12/22
  • IV Low 20.31% on 06/21/23
  • Put/Call Vol Ratio 0.03
  • Today's Volume 3,824
  • Volume Avg (30-Day) 972
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 54,897
  • Open Int (30-Day) 51,794

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 0.15
  • Number of Estimates 8
  • High Estimate 0.23
  • Low Estimate 0.11
  • Prior Year 0.22
  • Growth Rate Est. (year over year) -31.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.64 +6.55%
on 06/14/23
20.02 -0.80%
on 06/22/23
+0.53 (+2.74%)
since 05/23/23
3-Month
17.90 +10.95%
on 03/24/23
20.56 -3.40%
on 04/06/23
+1.53 (+8.35%)
since 03/23/23
52-Week
14.87 +33.56%
on 10/11/22
22.47 -11.62%
on 07/06/22
-1.47 (-6.89%)
since 06/23/22

Most Recent Stories

More News
3 No-Brainer Stocks to Buy With $200 Right Now

A modest amount of money can go a long way when it's invested in game-changing businesses.

COMP : 3.07 (-2.23%)
DIS : 88.10 (-0.44%)
EXEL : 19.86 (-0.10%)
SBUX : 98.34 (-2.49%)
3 Biotech Stocks With Great Value

The global demand for healthcare and biotech products continues to grow, owing to factors such as increasing chronic diseases and a greater focus on personalized medicine. Therefore, it might be wise to...

BMRN : 93.50 (-2.21%)
EXEL : 19.86 (-0.10%)
THTX : 0.8802 (-5.34%)
The Smartest Stocks to Buy With $20 Right Now and Hold Forever

These companies can take investors on a lucrative ride, and all for the price of a few lattes.

EXEL : 19.86 (-0.10%)
SNAP : 10.82 (+1.69%)
2 Under-the-Radar Biotech Stocks to Buy in 2023

Companies that don't make a lot of noise can still make you a lot of money.

EXEL : 19.86 (-0.10%)
SRPT : 114.09 (-7.93%)
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond

Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines.

AXSM : 88.11 (-2.48%)
EXEL : 19.86 (-0.10%)
2 Explosive Biotech Stocks to Own

The biotech industry is well-positioned to grow, thanks to breakthrough advances, rising chronic illness and government support. So, fundamentally solid biotech stocks, Genmab (GMAB) and Exelixis (EXEL)...

ARGX : 396.39 (-1.04%)
EXEL : 19.86 (-0.10%)
GMAB : 38.38 (-0.26%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 28.92 (-5.68%)
RARE : 50.20 (-2.62%)
SRPT : 114.09 (-7.93%)
PFE : 38.30 (-1.11%)
EXEL : 19.86 (-0.10%)
MRNA : 118.50 (-1.64%)
UTHR : 222.36 (-1.27%)
BIIB : 284.52 (-3.21%)
SNY : 53.30 (unch)
LLY : 458.84 (+0.25%)
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip

A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals.

COMP : 3.07 (-2.23%)
$NASX : 13,492.52 (-1.01%)
PINS : 26.24 (+0.38%)
EXEL : 19.86 (-0.10%)
RDFN : 10.32 (-2.92%)
IIPR : 70.59 (-3.02%)
BIDU : 139.29 (-1.85%)
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

BMY : 65.04 (-0.40%)
EXEL : 19.86 (-0.10%)
LGND : 73.09 (-3.41%)
SPRO : 1.6000 (+8.84%)
Exelixis (EXEL) Q1 2023 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2023.

EXEL : 19.86 (-0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 20.27
2nd Resistance Point 20.13
1st Resistance Point 20.00
Last Price 19.86
1st Support Level 19.72
2nd Support Level 19.58
3rd Support Level 19.45

See More

52-Week High 22.47
Last Price 19.86
Fibonacci 61.8% 19.57
Fibonacci 50% 18.67
Fibonacci 38.2% 17.77
52-Week Low 14.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar